Literature DB >> 12621240

Effects of therapy on dentofacial development in long-term survivors of head and neck rhabdomyosarcoma: the memorial sloan-kettering cancer center experience.

Cherry L Estilo1, Joseph M Huryn, Dennis H Kraus, Charles A Sklar, Leonard H Wexler, Suzanne L Wolden, Ian M Zlotolow.   

Abstract

PURPOSE: To describe potential effects of multimodality therapy on dental and facial development in long-term survivors of head and neck rhabdomyosarcoma. PATIENTS AND METHODS: The medical records of all patients aged 20 years or less presenting between 1985 and 1996 with a diagnosis of rhabdomyosarcoma and treated by protocol were reviewed. Head and neck rhabdomyosarcoma patients who were followed in the Dental Service and were alive and free of disease with at least a 5-year follow-up were included in the review. Ten patients satisfied the inclusion criteria and form the basis of this report. The median age at diagnosis of the 10 patients was 4.3 years (range 10 months to 19.5 years). All patients were treated with chemotherapy, two patients underwent surgery, and all but one patient received external beam radiation therapy.
RESULTS: Clinical or radiographic dentofacial abnormalities were observed in 8 of the 10 (80%) patients. Abnormalities included enamel defects, bony hypoplasia/facial asymmetry, trismus, velopharyngeal incompetency, tooth/root agenesis, and disturbance in root development. Bony hypoplasia and disturbance in root formation were the most common findings.
CONCLUSIONS: Multimodality therapy for head and neck rhabdomyosarcoma can result in dentofacial abnormalities that affect the patient's quality of life. The care of the long-term survivor requires a multidisciplinary approach, including early involvement of the dental team.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12621240     DOI: 10.1097/00043426-200303000-00007

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  8 in total

1.  Hypodontia and hypoplasia of mandible: A rare defect caused by combination therapy.

Authors:  Senthil Kumar; Nazargi Mahabob
Journal:  J Pharm Bioallied Sci       Date:  2013-07

Review 2.  Epidemiology and treatment of head and neck malignancies in the AYA generation.

Authors:  Takahiro Asakage
Journal:  Int J Clin Oncol       Date:  2022-01-14       Impact factor: 3.402

Review 3.  A systematic review of dental disease in patients undergoing cancer therapy.

Authors:  Catherine H L Hong; Joel J Napeñas; Brian D Hodgson; Monique A Stokman; Vickie Mathers-Stauffer; Linda S Elting; Fred K L Spijkervet; Michael T Brennan
Journal:  Support Care Cancer       Date:  2010-05-07       Impact factor: 3.603

4.  Long-term effect of chemotherapy-intensity-modulated radiation therapy (chemo-IMRT) on dentofacial development in head and neck rhabdomyosarcoma patients.

Authors:  Adepitan A Owosho; Paul Brady; Suzanne L Wolden; Leonard H Wexler; Cristina R Antonescu; Joseph M Huryn; Cherry L Estilo
Journal:  Pediatr Hematol Oncol       Date:  2016-09-30       Impact factor: 1.969

5.  Chiari I malformation after cranial radiation therapy in childhood: a dynamic process associated with changes in clival growth.

Authors:  Kristian Aquilina; Thomas E Merchant; Frederick A Boop; Robert A Sanford
Journal:  Childs Nerv Syst       Date:  2009-11       Impact factor: 1.475

6.  Dental Care for Survivors of Adolescent and Young Adult Cancer: Special Considerations.

Authors:  Sapna Kaul; Douglas Fair; Jennifer Wright; Anne C Kirchhoff
Journal:  J Adolesc Young Adult Oncol       Date:  2016-03-30       Impact factor: 2.223

Review 7.  Survivors of childhood and adolescent cancer: life-long risks and responsibilities.

Authors:  Leslie L Robison; Melissa M Hudson
Journal:  Nat Rev Cancer       Date:  2013-12-05       Impact factor: 60.716

8.  Oral rehabilitation with implant-based prostheses of two adult patients treated for childhood rhabdomyosarcoma.

Authors:  Anke Korfage; Kees Stellingsma; Johan Jansma; Arjan Vissink; Gerry M Raghoebar
Journal:  Support Care Cancer       Date:  2011-07-13       Impact factor: 3.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.